Status:

COMPLETED

Loreline Study: Characterization of Long Responders Under Eribuline

Lead Sponsor:

Centre Jean Perrin

Conditions:

Breast Cancer Patients

Therapy Related Tumor

Eligibility:

FEMALE

18-75 years

Brief Summary

There is currently no strict recommendations for the management of patients who have received at least one or two lines of anthracyclines-based chemotherapy and taxane therapy for advanced breast canc...

Detailed Description

The investigators will perform a cross-sectional study in patients with metastatic breast cancer who have failed treatment after the first line and beyond. In this study, the investigators will be pa...

Eligibility Criteria

Inclusion

  • Women aged between 18 and 75 years
  • Metastatic breast cancer patient
  • Patients treated by Halaven® in second, third or fourth line of treatment for their metastatic breast cancer
  • Halaven® treatment must have been received between September 2011 and December 2016
  • Patients responding or in stability during at least 6 months under Halaven® treatment
  • Patients pretreated by at least one line of any other chemotherapy
  • Non opposition form dated and signed by the investigator (attesting that the patient consented orally that clinical, biological and imaging data concerning her were analyzed in this study)

Exclusion

  • Male
  • Patient with cognitive and psychiatric disorders
  • Patient deprived of liberty by judicial or administrative decision
  • Insufficient knowledge or understanding of the French language which does not allow for the non-opposition form to be understood

Key Trial Info

Start Date :

August 23 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

February 28 2021

Estimated Enrollment :

97 Patients enrolled

Trial Details

Trial ID

NCT03771183

Start Date

August 23 2019

End Date

February 28 2021

Last Update

April 5 2021

Active Locations (5)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (5 locations)

1

CHRU Jean Minoz

Besançon, France, 25030

2

Centre Jean Perrin

Clermont-Ferrand, France, 63011

3

Institut de Cancérologie Lucien Neuwirth

Saint-Priest-en-Jarez, France, 42270

4

Centre Paul Strauss

Strasbourg, France, 67065

Loreline Study: Characterization of Long Responders Under Eribuline | DecenTrialz